Join to View Full Profile
341 Ponce de Leon Ave NEAtlanta, GA 30308
Phone+1 404-616-2440
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Valeria Cantos Lucio, MD is an infectious disease specialist in Atlanta, Georgia. She is currently licensed to practice medicine in Georgia.
Education & Training
Emory University School of MedicineResidency, Internal Medicine, 2010 - 2013
Pontifical Catholic University of EcuadorClass of 2006
Certifications & Licensure
GA State Medical License 2012 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 25 citationsTwice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.Colleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, Anchalee Avihingsanon, Paul Benson
The New England Journal of Medicine. 2025-04-03 - 2 citationsEarly Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.Dylan Baker, Lauren F Collins, Valeria D Cantos, Emma Hollenberg, Alexander Kaplan
Journal of General Internal Medicine. 2025-02-11 - 2 citationsDevelopment of a home-based pre-exposure prophylaxis care delivery system for long-acting injectable cabotegravir: a formative exploration of patient preferences.Janelly Gonzalez, Paulina A Rebolledo, Aaron J Siegler, Wenting Huang, Kenneth H Mayer
AIDS Care. 2024-12-01
Press Mentions
Clinical Trial Reveals Twice-Yearly Injection to Be 96% Effective in HIV PreventionDecember 4th, 2024- Twice-Yearly Injections Are 99% Efficient at Preventing HIV, According to a Clinical StudyNovember 30th, 2024
- New HIV Prevention Injection Offers 96% ProtectionNovember 28th, 2024
